Chemed Corporation
CHE
$421.11
+9.96%
Chemed Corporation operates two distinct business segments: VITAS, a leading provider of hospice and palliative care services, and Roto-Rooter, a well-known plumbing and drain cleaning service. The company is a market leader in both the hospice care and residential/commercial plumbing industries, leveraging strong brand recognition and operational scale. The current investor narrative is shaped by a significant stock price decline over the past year, juxtaposed with management's aggressive capital return policy, highlighted by a recent $300 million share repurchase authorization and a steady dividend, signaling confidence in its cash-generating ability despite market headwinds.…
CHE
Chemed Corporation
$421.11
Related headlines
Investment Opinion: Should I buy CHE Today?
Rating: Hold. The core thesis is that CHE is a cash-generative market leader facing significant but potentially transient operational headwinds; the stock is fairly valued at current levels as it balances these risks against aggressive capital returns, but lacks a clear near-term catalyst for a re-rating.
Supporting Evidence: The forward P/E of 14.45x, based on estimated EPS of $28.9, prices in a meaningful earnings recovery and sits at a discount to the trailing multiple, providing a valuation cushion. The company's robust free cash flow yield of ~5.3% and strong balance sheet (D/E 0.16) underpin the $300M buyback authorization, which provides tangible support for per-share metrics. However, flat revenue growth (-0.1% YoY) and severe margin compression (gross margin down 436 bps YoY) substantiate the bear case and justify the stock's -33.9% annual decline and analyst downgrades.
Risks & Conditions: The two biggest risks are 1) further margin deterioration invalidating the forward earnings estimates, and 2) a failure of buybacks to offset fundamental erosion, leading to further multiple compression. This Hold rating would upgrade to Buy if QoQ gross margins show sequential stabilization or improvement, or if the forward P/E compressed below 13x on sustained earnings. It would downgrade to Sell if revenue growth turns negative beyond -2% or if TTM free cash flow declines by more than 15%. Based on the current data, the stock appears fairly valued relative to its near-term prospects, trading at a discount to its own history but not necessarily to its diminished growth profile.
Sign up to view all
CHE 12-Month Price Forecast
CHE presents a classic 'show me' story. The valuation has reset to a level that discounts much of the bad news, and the shareholder return policy is compelling. However, the fundamental picture must stop deteriorating for the thesis to work. The neutral stance reflects high uncertainty around the sustainability of margins in the core VITAS business. Confidence is medium because the company's financial strength provides a buffer, but the operational headwinds are significant. The stance would upgrade to bullish on concrete evidence of margin stabilization for two consecutive quarters. It would turn bearish on a breakdown below the 52-week low on high volume, signaling a failure of the current valuation support.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Chemed Corporation's 12-month outlook, with a consensus price target around $547.44 and implied upside of +30.0% versus the current price.
Average Target
$547.44
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$337 - $547
Analyst target range
Analyst coverage for CHE appears limited, with data indicating only one analyst providing estimates for revenue and EPS, but no consensus recommendation or price target data is provided in the 'Analyst data' field. The provided 'Institutional ratings' show a recent shift in sentiment, with RBC Capital downgrading from Outperform to Sector Perform and Jefferies downgrading from Buy to Hold in early 2026, following the company's earnings report. Conversely, Oppenheimer maintained an Outperform rating. This pattern of recent downgrades to more neutral stances reflects growing caution among analysts following the stock's underperformance and margin compression. The lack of a broad consensus target price and the downgrade activity signal high uncertainty and a lack of strong bullish conviction in the near term, which is typical for a stock undergoing a fundamental re-rating.
Bulls vs Bears: CHE Investment Factors
The evidence currently tilts bearish, as the fundamental deterioration in profitability and growth is severe and has triggered a massive re-rating. The bull case rests almost entirely on the expectation that current margins represent a trough and that aggressive buybacks will support per-share value. The single most important tension in the investment debate is whether the significant margin compression in the VITAS segment is a transient issue related to labor or reimbursement pressures, or a structural decline that permanently impairs the business's earning power. The resolution of this margin trajectory will determine if the stock is a deep-value turnaround or a value trap.
Bullish
- Strong Free Cash Flow & Shareholder Returns: The company generated $325.5 million in TTM free cash flow, representing a robust 5.3% yield based on market cap. This funds aggressive capital returns, including $174.6 million in Q4 share repurchases and a new $300 million buyback authorization, signaling management's confidence in the underlying cash-generating business.
- Compelling Forward Valuation: The stock trades at a forward P/E of 14.45x based on estimated EPS of $28.9, a significant discount to its trailing P/E of 23.23x. This implies the market has priced in the recent earnings decline and expects a meaningful profit recovery, offering a potential valuation floor.
- Healthy Balance Sheet: Chemed maintains a low debt-to-equity ratio of 0.16, providing significant financial flexibility. This low leverage, combined with strong cash generation, insulates the company from financial distress and supports continued shareholder returns even during operational headwinds.
- Market Leadership in Stable Industries: The company holds leading positions in hospice care (VITAS, 67% of revenue) and plumbing services (Roto-Rooter), both of which are essential, non-discretionary services. This provides a defensive revenue base, as evidenced by revenue remaining relatively stable between $590M and $646M over the last eight quarters despite market pressures.
Bearish
- Severe Profitability Compression: Gross margin collapsed to 32.22% in Q4 2025 from 36.58% a year prior, and operating margin fell to 15.74% from 17.79%. This 430+ basis point gross margin contraction directly drove the 33.9% year-over-year decline in Q4 net income, indicating significant operational headwinds.
- Stagnant Revenue Growth: Revenue growth is effectively flat, with Q4 2025 revenue of $639.3 million showing a -0.1% year-over-year change. The business has shown no top-line expansion for multiple quarters, highlighting its mature nature and lack of a clear growth catalyst.
- Extreme Relative Underperformance: The stock has underperformed the S&P 500 by -68.78% over the past year, with a total 1-year return of -33.88%. This severe decoupling from the market rally, despite a low beta of 0.484, indicates deep-seated, company-specific issues that have eroded investor confidence.
- Analyst Downgrades & Lack of Conviction: Recent institutional ratings show downgrades from RBC Capital (Outperform to Sector Perform) and Jefferies (Buy to Hold). The lack of a broad analyst consensus and this shift to neutral stances reflects high uncertainty and a lack of near-term bullish catalysts following the earnings report.
CHE Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -33.88%, and is currently trading near the bottom of its 52-week range, at $384.61 versus a 52-week high of $593.8 and low of $365.21. This positioning near the lows suggests a potential value opportunity but also reflects significant negative momentum and investor pessimism. Recent momentum shows a slight 1-month gain of 0.37%, which contrasts sharply with the deeper 3-month decline of -14.89%, indicating a potential attempt at stabilization or a minor bounce within a broader bearish trend. However, the stock has demonstrated severe relative weakness, underperforming the S&P 500 by -68.78% over one year, highlighting its significant decoupling from the broader market rally. Key technical support is the 52-week low of $365.21, while resistance lies at the recent breakdown level around $478.54 from late February. A breakdown below $365.21 could signal further downside, while a sustained move above $400-$410 is needed to suggest a near-term base is forming. The stock's low beta of 0.484 indicates it is less volatile than the market, which is unusual given its recent sharp decline, suggesting the sell-off has been driven by company-specific factors rather than market-wide risk.
Beta
0.48
0.48x market volatility
Max Drawdown
-40.5%
Largest decline past year
52-Week Range
$365-$584
Price range past year
Annual Return
-23.0%
Cumulative gain past year
| Period | CHE Return | S&P 500 |
|---|---|---|
| 1m | +12.6% | +8.7% |
| 3m | -5.7% | +3.6% |
| 6m | -3.6% | +5.4% |
| 1y | -23.0% | +30.6% |
| ytd | -0.6% | +4.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CHE Fundamental Analysis
Revenue growth has stagnated, with Q4 2025 revenue of $639.34 million showing essentially flat year-over-year growth at -0.1%. The multi-quarter trend shows revenue has been range-bound between approximately $590 million and $646 million over the last eight quarters, indicating a mature business with limited top-line expansion. Segment data for the latest period shows the VITAS hospice segment generated $429.85 million (67% of revenue) and Roto-Rooter contributed $231.59 million, but growth trends for each are not specified in the provided data. The company remains profitable, with Q4 2025 net income of $76.75 million, translating to a net margin of 12.0%. However, profitability has compressed year-over-year, as gross margin declined to 32.22% in Q4 2025 from 36.58% in Q4 2024, and operating margin fell to 15.74% from 17.79% over the same period, indicating margin pressure. The balance sheet is healthy with a low debt-to-equity ratio of 0.158, and the company generates robust free cash flow, with TTM free cash flow of $325.48 million. This strong cash generation, evidenced by a free cash flow yield of approximately 5.3% based on market cap, funds aggressive shareholder returns, including $174.56 million in stock repurchases in Q4 2025 alone, underscoring financial flexibility.
Quarterly Revenue
$639337000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.32%
Latest Quarter
Free Cash Flow
$325477000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CHE Overvalued?
Given a positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 23.23x, while the forward P/E is notably lower at 14.45x, based on estimated EPS of $28.9. This significant gap implies the market expects a substantial earnings recovery in the coming year, pricing in improved profitability. Compared to sector averages, data is not available in the provided inputs for a direct industry P/E comparison. However, the stock's own historical P/E context is informative: the current trailing P/E of 23.23x is below its recent historical range, which has fluctuated between approximately 19.5x and 38.2x over the past several quarters. Trading near the lower end of its own historical valuation band suggests the market has priced in the recent fundamental deterioration, potentially limiting further multiple compression barring additional negative surprises.
PE
23.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 20x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is sustained margin erosion, as evidenced by the 430+ basis point year-over-year gross margin decline. This compression directly threatens the company's ability to maintain its current level of profitability and free cash flow generation, which is the cornerstone of its shareholder return policy. Revenue concentration in the VITAS hospice segment (67% of sales) exposes the company to regulatory changes in Medicare reimbursement and labor cost inflation specific to healthcare, which are likely drivers of the recent margin pressure. While the balance sheet is strong (D/E of 0.16), a continuation of these trends could force a reduction in the aggressive buyback pace, removing a key support for the stock.
Market & Competitive Risks: The stock faces significant valuation compression risk. Its trailing P/E of 23.23x, while below its own history, may still be considered rich for a company with negative revenue growth and declining margins, especially if compared to more stable healthcare or service peers. The recent analyst downgrades to Sector Perform and Hold reflect a loss of growth narrative and a shift to a 'show me' story, which typically limits multiple expansion. Furthermore, the stock's low beta of 0.484 did not protect it from a -34% drawdown, indicating it is vulnerable to idiosyncratic, non-systematic risks that are difficult to hedge.
Worst-Case Scenario: The worst-case scenario involves the margin compression in the VITAS business proving to be structural rather than cyclical, driven by permanent reimbursement cuts and unsustainable labor costs. This would lead to consecutive earnings misses, a halt in share repurchases to conserve cash, and a loss of the dividend. In this adverse scenario, the stock could re-test and break below its 52-week low of $365.21, potentially falling towards a bear-case P/E of 12-13x on depressed earnings, implying a downside of -20% to -25% from the current price. The maximum drawdown from the 52-week high is already -40.47%, highlighting the severity of the existing decline.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued margin erosion in the VITAS hospice segment, as seen in the 436 bps gross margin decline, which could be structural. 2) Growth Risk: Permanent stagnation or decline in revenue, removing any top-line catalyst. 3) Valuation Risk: Further multiple compression if the expected earnings recovery fails, potentially driving the stock below its 52-week low of $365.21. 4) Sentiment Risk: The stock has shown extreme idiosyncratic weakness (-68.78% relative to SPY), indicating it can fall independently of the broader market, making timing difficult.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $380 and $430, assuming margins stabilize and buybacks provide support. The Bull Case (25% probability) targets $460-$520 on successful margin recovery and multiple expansion. The Bear Case (20% probability) warns of a drop to $330-$365 if operational deterioration continues. The base case is most likely, centered on the current forward P/E and estimated EPS, but its realization hinges critically on the next few quarters of margin performance.
CHE appears fairly valued relative to its near-term prospects. The forward P/E of 14.45x is a 38% discount to the trailing P/E of 23.23x, indicating the market has priced in a significant earnings decline and is betting on a recovery. Compared to its own historical P/E range (approx. 19.5x to 38.2x), it trades near the lower end, suggesting limited multiple compression risk. However, given the lack of revenue growth and margin pressure, the current valuation is not a clear bargain and implies the market expects management to successfully navigate the current operational challenges.
CHE is a speculative buy only for investors with a high risk tolerance and a long-term horizon who believe in a margin recovery. The stock offers a compelling forward P/E of 14.45x and a strong 5.3% free cash flow yield funding buybacks, which provides downside support. However, it carries significant risk from severe profitability compression (-436 bps gross margin YoY) and flat revenue growth. It is not a good buy for growth investors or those seeking low-volatility income, but may appeal to deep-value investors betting on a cyclical rebound in the hospice business.
CHE is unsuitable for short-term trading due to its low beta (0.484) but high idiosyncratic volatility and lack of near-term catalysts. It is best considered a long-term investment (minimum 2-3 years) for investors who believe in the durability of its hospice and plumbing franchises and their ability to regain pricing power and margin stability. The aggressive buyback program is a long-term value-creation mechanism. The stock's 0.5% dividend yield is nominal, so it is not an income play. Given the need for a fundamental turnaround to materialize, a long horizon is required to allow the thesis to play out.
